Dimitrios Zampatis | Global Program Safety Lead
Novartis AG

Dr. Dimitris Zampatis is Global Program Safety Lead at Novartis, overseeing safety strategy for complex global development programs across early‑ and late‑phase clinical trials as well as post‑marketing activities. With more than 15 years of experience in pharmacovigilance, he leads cross‑functional safety governance, drives signal detection and evaluation, and shapes risk‑management strategies that support major regulatory submissions to EMA, FDA, PMDA, and TGA. His work focuses on strengthening benefit–risk assessment frameworks, embedding quantitative methodologies, and advancing the integration of AI‑enabled tools into modern safety surveillance. Dr. Zampatis holds degrees in biology (Bsc), medicinal chemistry (MSc), health policy (MSc), molecular biology (PhD), and an Executive MBA. He is also an adjunct lecturer and frequent speaker at international conferences, contributing to the global dialogue on innovation in drug safety and clinical research.